Convergent model reveals TLR7 and EBV's roles in systemic lupus erythematosus, suggesting treatments.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by a type I interferon signature, B cell hyperactivity, and loss of CD8-mediated control of Epstein-Barr virus (EBV). Here we present a convergent model integrating five EBV mechanisms that simultaneously amplify the TLR7→IRF7→BAFF→IFN feedback loop and disable the CD8 response that should control it. The model integrates: (1) BGLF2-mediated STAT2 degradation in CD8 T cells, confirmed across 924 SLE patients (GSE65391); (2) LMP1 constitutive CD40 signaling compensating for low CD40LG; (3) EBNA2 reprogramming of B cells as antigen-presenting cells (Younis/Robinson 2025, Sci TM); (4) EBERs activating TLR7 → IFN production; and (5) LMP1 driving NF-κB through defective A20 (TNFAIP3, rs2230926). Key findings: STAT2 is significantly reduced in SLE CD8 cells, identifying BGLF2-mediated STAT2 degradation as the mechanistic link between EBV and CD8 dysfunction. A20 (rs2230926) dysfunction removes the brake on LMP1-driven NF-κB activation. The TLR7→BAFF→IFN loop is invariant across all affected organs (renal, mucocutaneous, hematologic) — a pre-existing systemic state rather than organ-specific. EBNA2 reprogramming of EBV-infected B cells into antigen-presenting cells drives autoreactive Tph and DN2 B cell expansion. Data sources: GSE65391 (n=924 pediatric SLE), GSE135779 (363,083 single cells), GSE50772, GSE81622, GSE72326, GSE119079, GSE72509 (n=996), GSE58484, GSE118253 (ATAC-seq), Baños 2021 (bone marrow CD34+), Younis/Robinson 2025 (EBV-seq). Without EBV, the core phenomena of SLE lack a mechanistic framework. With EBV — including BGLF2 degradation of STAT2, LMP1 hijacking of CD40, EBNA2 reprogramming of B cells, EBER activation of TLR7, and LMP1 exploitation of broken A20 — they converge into a testable model with immediate therapeutic implications including sirolimus for mTOR blockade and maribavir for reducing EBV viral load.
No takes yet. Share an insight, caveat, or question.
Javier Martínez Mellado (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: